Literature DB >> 2156645

A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects.

A P Davenport1, M J Ashby, P Easton, S Ella, J Bedford, C Dickerson, D J Nunez, S J Capper, M J Brown.   

Abstract

1. A radioimmunoassay has been developed for measuring endothelin-like immunoreactivity in human plasma using an antibody raised against endothelin-1 which also cross-reacts with big endothelin-1 and endothelin-2 but not endothelin-3. 2. The sensitivity of the assay was 1 fmol/tube with inter- and intra-assay coefficients of variation of 13% and 9%, respectively. Cross-reactivity with endothelin-3 and non-endothelin peptides was less than 1%. 3. Endothelin-like immunoreactivity was present in the plasma of hypertensive patients (n = 25) at a concentration of 5.7 +/- 0.5 pmol/l (mean +/- SEM), which was not significantly different from that of age-matched control subjects (5.1 +/- 0.5 pmol/l). At these levels, endothelin-1 is unlikely to function as a circulating hormone. 4. Within the normotensive group, the concentration of endothelin-like immunoreactivity in plasma was positively correlated with mean arterial blood pressure, but in hypertensive patients it showed a significant negative correlation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156645     DOI: 10.1042/cs0780261

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  30 in total

1.  Higher circulatory level of endothelin-1 in hypertensive subjects screened through a cross-sectional study of rural Bangladeshi women.

Authors:  Shamima Akter; Subrina Jesmin; Yoshio Iwashima; Sakuramoto Hideaki; Md Arifur Rahman; Md Majedul Islam; Masao Moroi; Nobutake Shimojo; Naoto Yamaguchi; Takashi Miyauchi; Satoru Kawano; Taro Mizutani; Yuhei Kawano
Journal:  Hypertens Res       Date:  2014-11-13       Impact factor: 3.872

Review 2.  Hypertension.

Authors:  G W Ching; D G Beevers
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 3.  Role of endothelin in the control of peripheral vascular tone in human hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Magagna; A Salvetti
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 4.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

5.  Serum endothelin concentrations in workers exposed to vibration.

Authors:  K T Palmer; H Mason
Journal:  Occup Environ Med       Date:  1996-02       Impact factor: 4.402

6.  Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis.

Authors:  J F Pittet; D R Morel; A Hemsen; K Gunning; J S Lacroix; P M Suter; J M Lundberg
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

7.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

8.  Pathophysiological significance of plasma endothelin in peripheral circulatory disturbances.

Authors:  H Nakamura; H Nagase; M Yoshida; T Okazawa; A Okada
Journal:  Environ Health Prev Med       Date:  1996-04       Impact factor: 3.674

Review 9.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

10.  Circulating endothelin in acute ischaemic syndromes.

Authors:  S G Ray; J J McMurray; J J Morton; H J Dargie
Journal:  Br Heart J       Date:  1992-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.